Our Mission: develop tumor-penetrating drugs

PDC/NDC is next-gen XDC modality: better tumor penetration, enhanced in vivo efficacy in large tumor CDX/PDX model over ADCs.

Reduced non-target distribution, suitable for optimal systemic exposure, improved safety.

Rapidly developing 5 oncology pipelines, clinical data of  SC-101 read-out in 2024.

About Conjustar

Tianjin Conjustar Biologics Co., Ltd. jointly incubated by Fosun Health Capital, the first VC fund established by Fosun Pharma and WuXi AppTec, our company is focused on developing novel peptide-drug conjugates (PDCs) and nanobody-drug conjugates (NDCs) that hold the potential to be best-in-class (BIC) and first-in-class (FIC) therapies for challenging oncology targets.

PDCs/NDCs, while maintaining high target binding capacity and selectivity comparable to that of ADCs, have better solid tumor penetration, thus providing therapeutic efficacy. Importantly, PDCs exhibit reduced non-target distribution, enabling optimal systemic exposure and improved safety profiles.

History

◆ In Jan 2025, PreA+ round of financing of 100 million RMB was obtained

◆ In 2024, 

   - First PDC  (SC-101) approved for IND by NMPA
   - SC-101 IND approved by US FDA
   - Second PDC  (SC-102) approved for IND by NMPA
   - Launched the construction of Zhuhai Research Center

   - PreA round of financing of 90 million RMB was obtained

◆ In February 2023, angel round of financing of 55 million RMB was obtained

◆ In August 2022, the Zhangjiang office of Conjustar was put into use
 

◆ In March 2022, 45.5 million RMB was obtained in seed funding
 

◆ In February 2022, Tianjin Conjustar Biologics Co., Ltd. was registered and established in Tianjin